Peptide Comparison
Nesiritide (BNP)vsBPC-157
Recombinant B-type natriuretic peptide that helps your heart breathe easier by reducing fluid overload and improving blood flow during acute heart failure crises.
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
Nesiritide (BNP)
0.01 mcg/kg/min–0.03 mcg/kg/min mcg
BPC-157
250–500 mcg
Frequency
Nesiritide (BNP)
Once daily
BPC-157
Once daily
Administration
Nesiritide (BNP)
Intravenous (IV) bolus
BPC-157
Subcutaneous injection
Cycle Length
Nesiritide (BNP)
Ongoing/indefinite
BPC-157
4-6 weeks
Onset Speed
Nesiritide (BNP)
Moderate (1-2 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
Nesiritide (BNP)
Strong human trials (Phase 3 or FDA approved)
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Rapid Symptom Relief
Fluid Management
Heart Workload Reduction
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
Nesiritide (BNP)
Molecular Formula
C143H244N50O42S4
Molecular Weight
3464.0 Da
Half-Life
18 minutes (terminal elimination half-life)
Bioavailability
100% (intravenous administration)
CAS Number
114471-18-0
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
Nesiritide (BNP)
BPC-157
Applications
Best
suited for
Nesiritide (BNP)
Emergency stabilization of acute heart failure episodes
Nesiritide (BNP) is particularly well-suited for individuals focused on emergency stabilization of acute heart failure episodes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Rapid relief of severe shortness of breath
Nesiritide (BNP) is particularly well-suited for individuals focused on rapid relief of severe shortness of breath. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing hospitalization time and improving outcomes
Nesiritide (BNP) is particularly well-suited for individuals focused on reducing hospitalization time and improving outcomes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing sudden fluid buildup in the lungs or legs
Nesiritide (BNP) is particularly well-suited for individuals focused on managing sudden fluid buildup in the lungs or legs. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
Nesiritide (BNP)
Common
- Headache
- Lightheadedness
- Back pain
Uncommon
- Hypotension (low blood pressure)
- Abdominal pain
- Insomnia
Serious
- Acute kidney injury
- Severe hypotension
- Allergic reaction
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
Nesiritide (BNP)
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
FDA-approved nesiritide (Natrecor) demonstrates excellent safety in acute decompensated heart failure with rapid onset (15-minute half-life providing quick reversibility). Symptomatic hypotension occurs in 11% of patients, managed through continuous IV monitoring and dose titration. No serious adverse events, carcinogenicity, or renal dysfunction directly attributable to nesiritide in Phase III trials (n=700+). Tachyphylaxis (tolerance) can develop with prolonged infusions beyond 24-48 hours.
Contraindications
- xSystolic blood pressure less than 90 mmHg
- xSevere renal impairment or kidney disease
- xCardiogenic shock or severe hypotension
- xAllergy to nesiritide or any ingredients
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose Nesiritide (BNP) if...
- Emergency stabilization of acute heart failure episodes
- Rapid relief of severe shortness of breath
- Reducing hospitalization time and improving outcomes
- Managing sudden fluid buildup in the lungs or legs
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health